Agios Pharmaceuticals (Agios Pharmaceuticals) Price-to-Tangible-Book : 2.18 (As of Apr. 24, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-24), Agios Pharmaceuticals's share price is $31.67. Agios Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $14.50. Hence, Agios Pharmaceuticals's Price to Tangible Book Ratio of today is 2.18.

The historical rank and industry rank for Agios Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

AGIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.38 Med: 5.01 Max: 9.8
Current: 2.18

During the past 13 years, Agios Pharmaceuticals's highest Price to Tangible Book Ratio was 9.80. The lowest was 1.38. And the median was 5.01.

AGIO's Price-to-Tangible-Book is ranked better than
57.64% of 1218 companies
in the Biotechnology industry
Industry Median: 2.69 vs AGIO: 2.18

A closely related ratio is called PB Ratio. As of today, Agios Pharmaceuticals's share price is $31.67. Agios Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $14.50. Hence, Agios Pharmaceuticals's P/B Ratio of today is 2.18.

Agios Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Agios Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Price-to-Tangible-Book Chart

Agios Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

5.10

7.52

1.38

1.40

1.54

Agios Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															1.40	1.23	1.64	1.56	1.54

Competitive Comparison of Agios Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Agios Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agios Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Price-to-Tangible-Book falls into.

Agios Pharmaceuticals Price-to-Tangible-Book Calculation

Agios Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	31.67	/	14.497
	=	2.18

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Agios Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Agios Pharmaceuticals (Agios Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

AGIO:Mexico 8AP:Germany 8AP:Germany

Address

88 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Executives

Brian Goff	director, officer: Chief Executive Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Sarah Gheuens	officer: Chief Medical Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James William Burns	officer: Chief Legal Officer	C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jacqualyn A Fouse	director	C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Tsveta Milanova	officer: Chief Commercial Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139
Cecilia Jones	officer: Chief Financial Officer	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Kaye I Foster-cheek	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Washburn Theodore James Jr.	officer: Principal Accounting Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey D Capello	director	C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Catherine E. Owen	director	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
David P Schenkein	director, 10 percent owner, officer: Chief Executive Officer	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Rahul D. Ballal	director	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Richa Poddar	officer: Chief Commercial Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Carman Alenson	officer: Principal Accounting Officer	88 SIDNEY STREET, CAMBRIDGE MA 02139